TAGRISSO® (osimertinib) | Lung Cancer

This website is intended for UK Healthcare professionals only. Other UK residents please visit astrazeneca.co.uk

Setting the standard

in advanced EGFRm NSCLC ^1-10

Tagrisso: Setting a benchmark for PFS^1,13

(vs placebo)

In locally advanced unresectable EGFRm NSCLC post CRT with the LAURA regimen

Explore LAURA

Setting the standard
Most prescribed EGFR TKI in UK¹²

More than 5,500 patients in England have been treated with TAGRISSO across all indications^*1–9

Review our quality of life data.

Explore QOL

EGFRm NSCLC targeted with osimertinib

TAGRISSO selectively targets EGFR sensitising mutations (ex19del and L858R) and the T790M acquired resistance mutation.^1,2,11

Learn more about how TAGRISSO works.

Explore MOA

TAGRISSO: Efficacy that puts patients first
in advanced EGFRm NSCLC

TAGRISSO intensified with chemotherapy pairs the longest reported survival benefit* while respecting patient experience.¹⁰

*mOS global phase 3 study in advanced EGFRm NSCLC as at September 2025

Explore FLAURA2

Resources to support you and your patients

Hard copy and digital tools to support patients and their treatment

Explore resources

TAGRISSO: Meaningful protection from recurrence in early resected EGFRm NSCLC

Offers curative intent through extended disease free survival¹⁵

Explore ADAURA

Prehabilitation in patients with lung cancer

Learn how introducing prehabilitation in all lung cancer patients could improve outcomes¹⁴

Explore prehabilitation

TAGRISSO intensified with chemotherapy in FLAURA2 regimen

Pairs the longest reported mOS survival benefit (global phase III) while respecting the patient experience.¹⁰

As at September 2025.

Explore FLAURA2

first
second

Explore the trials:

ADAURA

Resectable Stage IB - IIIA EGFRm NSCLC  

Explore ADAURA

FLAURA

Advanced metastatic (Stage IV) EGFRm NSCLC  

Explore FLAURA

FLAURA2

Advanced metastatic (Stage IV) EGFRm NSCLC, TAGRISSO with platinum pemetrexed chemotherapy

Explore FLAURA2

LAURA

Unresectable Stage III EGFRm NSCLC  

Explore LAURA

Indications

TAGRISSO (osimertinib) as monotherapy is indicated for:^1,2

the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or exon 21 (L858R) substitution mutations
the treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations and whose disease has not progressed during or following platinum-based chemoradiation therapy
the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations
the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC

TAGRISSO is indicated in combination with:

pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced NSCLC whose tumours have EGFR ex19del or L858R mutations

Resources available

Supporting materials for you and your patients

Explore Resources

EGFR, epidermal growth factor receptor; EGFRm, epidermal growth factor receptor mutant; MOA, mechanism of action; NSCLC, non-small cell lung cancer

*based on NHS initiations as per Blueteq, December 2024.

TAGRISSO (osimertinib) 40 mg Summary of Product Characteristics.
TAGRISSO (osimertinib) 80 mg Summary of Product Characteristics.
Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023 Apr;34(4):339-357.
Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2020 Jan 2;382(1):41-50.
Leighl NB, Karaseva N, Nakagawa K, Cho B-C, Gray JE, Hovey T, et al. Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR mutated advanced non-small-cell lung cancer. Eur J Cancer. 2020 Jan:125:49-57.
Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, et al. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer. J Clin Oncol. 2018 Aug 28:JCO2018783118.
Planchard D, Janne PA, Cheng Y, Yang JCH, Yanagitani N, Kim SW, et al. N Engl J Med. 2023 Nov 23;389(21):1935-1948.
Lee CK, et al. First-line osimertinib ± platinum-pemetrexed in EGFRm advanced NSCLC: FLAURA2 patient-reported outcomes. Presented at the ELCC, 20th-23rd March 2024, Prague.
AstraZeneca. Data on File: 2025 BTOG Patient numbers Totem; 2025.
Jӓnne P, Planchard D, et al; Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med 2025; published online DOI: 10.1056/NEJMoa2510308.
Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4(9):1046-61.
AstraZeneca. Data on file. REF-259878. KPI Summary: TAGRISSO (FLAURA/FLAURA2), Q4 2024
Lu S, Kato T, Dong X, Ahn MJ, Quang LV, Soparattanapaisarn N, et al. Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. N Engl J Med. 2024 Aug 15;391(7):585-97.
Bloom E. Macmillan Cancer Support Prehabilitation Evidence and Insight Review. 2017. Available at: https://www.macmillan.org.uk/dfsmedia/1a6f23537f7f4519bb0cf14c45b2a629/23904-10061/prehabilitation-evidence-and-insight-review. Last accessed April 2026.
Tsuboi M, et al. Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non small cell lung cancer (NSCLC): Updated results from ADAURA. Presented at ESMO Congress, 9th–13th September 2022, Paris. Abstract #LBA47.

GB-77319 | June 2026

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling ‌‌‌0‌‌‌8‌‌‌‌‌0‌‌‌‌0‌‌‌ ‌‌7‌‌‌‌‌‌8‌‌‌3‌‌‌ ‌‌0‌‌‌‌‌0‌‌‌‌3‌‌‌‌3‌‌‌.

This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.

Cookie Policy

Setting the standard in advanced EGFRm NSCLC 1-10

Tagrisso: Setting a benchmark for PFS1,13

Setting the standard Most prescribed EGFR TKI in UK12

EGFRm NSCLC targeted with osimertinib

TAGRISSO: Efficacy that puts patients first in advanced EGFRm NSCLC

TAGRISSO: Meaningful protection from recurrence in early resected EGFRm NSCLC

Prehabilitation in patients with lung cancer

Explore the trials:

Indications

TAGRISSO (osimertinib) as monotherapy is indicated for:1,2

TAGRISSO is indicated in combination with:

Resources available

Abbreviations and References

Setting the standard

in advanced EGFRm NSCLC ^1-10

Tagrisso: Setting a benchmark for PFS^1,13

Setting the standard
Most prescribed EGFR TKI in UK¹²

TAGRISSO: Efficacy that puts patients first
in advanced EGFRm NSCLC

TAGRISSO (osimertinib) as monotherapy is indicated for:^1,2